New lens aims to sharpen Mid-Range vision after cataract removal

NCT ID NCT06333015

Completed Disease control Sponsor: Bausch & Lomb Incorporated Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This study tests a new type of artificial lens (enVista Beyond) for people having cataract surgery. The lens is designed to improve intermediate vision, like seeing a computer screen, while still providing good distance and near vision. About 304 adults will receive the lens in both eyes and be followed for several months to check safety and effectiveness compared to a standard lens.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: enVista Beyond Extended Depth of Focus Intraocular Lens (device)
What this could lead to: If successful, this lens could give cataract patients better intermediate vision (like seeing a computer screen) without needing glasses, while still seeing well at distance and near.
What could go wrong: This is a mid-stage study with 304 participants, so results may not apply to everyone. Some people may still need glasses for certain tasks, and there are typical surgical risks like infection or lens dislocation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CATARACT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cataract

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CATARACT

Contacts and locations

Locations

Site 101

Omaha, Nebraska, 68137, United States
Site 102

Brecksville, Ohio, 44141, United States
Site 103

Dallas, Texas, 75243, United States
Site 105

North Charleston, South Carolina, 29406, United States
Site 106

Sioux Falls, South Dakota, 57108, United States
Site 107

Bloomington, Minnesota, 55420, United States
Site 108

Northridge, California, 91325, United States
Site 109

Las Vegas, Nevada, 89145, United States
Site 111

Mount Pleasant, Wisconsin, 53405, United States
Site 112

San Antonio, Texas, 78229, United States
Site 113

Garden City, New York, 11530, United States
Site 115

Sugar Land, Texas, 77478, United States
Site 116

Alexandria, Minnesota, 56308, United States
Site 117

San Antonio, Texas, 78209, United States
Site 118

West Fargo, North Dakota, 58078, United States
Site 119

Dothan, Alabama, 36301, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.